GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>In any event, the goats will still have a major cost advantage.<

Yes and that's what started the thread--I was trying to make
the point that being the low-cost supplier of merchant protein
trumps the calculus of proprietary application. No
matter what the molecule is good for--and that's usually a
moving target, witness viagra which is now returning to its
clinical roots in the cardiosphere--we stand to benefit from
its therapeutic employment.

I think the FoB propaganda war is winding down and the only
aspect still in play is duration of exclusivity (maybe a bit
of data access too), and that BIO is not going to enjoy the
Obama administration.